Researchers at Hospital for Special Surgery in New York City have identified a protein, known as IRHOM2, as the potential new target for drugs to treat patients with rheumatoid arthritis (RA). The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway. “This study is an elegant example of the capacity of basic science cell biologists to work with translational rheumatologists to...
0 Responses to New drug target for rheumatoid arthritis identified